Feb 14, 2024 / 06:20PM GMT
Hartaj Singh - Oppenheimer & Co. Inc., Research Division - Research Analyst
Great. Thank you, everybody, for joining us on the second day here of this track with the Oppenheimer Healthcare Conference of 2024. Got David Snow, the SVP and the Global Head of Dupixent franchise and Ryan Crowe, the SVP of IR joining us here giving us a presentation, which I'm really looking forward to. Regeneron has been always a constant supporter of ours at our healthcare conferences. Really appreciate having them back.
David will give us an update on DUPIXENT. And then from there, we can jump into our fireside chat or just an overall update on the franchise, and we can jump into the fireside chat after that. So please take it away.
Ryan Crowe - Regeneron Pharmaceuticals, Inc. - VP of IR
Thank you, Hartaj and always great to be a part of the Oppenheimer Healthcare Conference, and Happy Valentine's Day to everybody out there.
Just do a quick forward-looking statement, and then I'll hand it over to David for some opening remarks before we get to Hartaj's
Regeneron Pharmaceuticals Inc at Oppenheimer Healthcare Life Sciences Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot